8-K: PetMed Express Appoints Peter Batushansky to Board of Directors, Gian Fulgoni to Retire

PetMed Express, Inc. announced the appointment of Peter Batushansky to its Board of Directors, effective April 9, 2025, while also announcing the upcoming retirement of longtime board member Dr. Gian Fulgoni at the 2025 annual shareholders meeting.

Summary

• PetMed Express, Inc. has appointed Peter Batushansky to its Board of Directors, effective April 9, 2025.
• Mr. Batushansky brings over 20 years of experience in retail, pet, healthcare, and private equity.
• He previously served as CEO of Allivet and WebEyeCare.
• He is currently a Partner at L2 Capital Partners.
• Dr. Gian Fulgoni, a longtime board member and former Chairman, will retire from the Board at the 2025 annual shareholders meeting.
• The Board size will be reduced from seven to six members upon Dr. Fulgoni's departure.
• Mr. Batushansky will serve on the Boards Audit Committee and Corporate Governance and Nominating Committee.
• He will receive compensation in accordance with the Companys Non-Employee Director Compensation Program.
• The company has appointed Ms. Campbell as Chairman of the Board in Q4 2024 and Ms. Campos appointment as the Companys new CEO and President in Q1 2025.
• Justin Mennen and Leah Solivan joined the Board during Q2 2025.
• With the appointment of Mr. Batushansky, the Board will be comprised of seven highly qualified and experienced directors, six of whom are independent, and three of whom have been added since 2024.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the addition of a new board member with relevant experience and the ongoing refreshment of the board. The retirement of a long-standing member is presented as a planned transition.

Positives

• The appointment of Peter Batushansky is expected to bring valuable perspective to the Board as the company executes its transformation plan.
• Mr. Batushansky's experience in scaling businesses in retail, pet, and healthcare aligns with the company's ambitions.
• The Board is being refreshed with new independent and highly qualified directors.
• The appointment of Ms. Campbell as Chairman of the Board in Q4 2024 and Ms. Campos appointment as the Companys new CEO and President in Q1 2025 signaled the start of this leadership transformation, followed by key hires in the roles of Chief Financial Officer, Chief Accounting Officer, Chief Operating Officer, and Chief Digital and Technology Officer.
• Justin Mennen and Leah Solivan joined the Board during Q2 2025.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties, as detailed in the company's filings with the SEC.
• The company's ability to meet the objectives included in its business plan is not guaranteed.

Future Outlook

The company aims to capitalize on its heritage as a pioneer in online pet pharmacy to expand its business across the broader pet wellness ecosystem, driving growth, profitability, and shareholder value.

Management Comments

• Leslie C. G. Campbell, Chairman of the Board, stated that Peter Batushansky's strategic vision and leadership experience will bring invaluable perspective as the company executes its transformation plan.
• Sandra Campos, President and CEO, commented that Peter Batushansky brings deep industry expertise and an exceptional track record in e-commerce.
• Peter Batushansky stated that it's exciting to join the Board at such a pivotal time in the Company's history.

Industry Context

The appointment of a new board member with experience in the pet industry and e-commerce suggests that PetMed Express is focusing on strengthening its position in the online pet healthcare market, which is experiencing growth and increased competition.

Comparison to Industry Standards

• PetMed Express's board composition aligns with industry standards, with a majority of independent directors.
• The company's focus on recruiting directors with relevant experience in retail, pet, healthcare, and private equity is a common practice among publicly traded companies.
• Comparable companies in the online pet healthcare market include Chewy and 1-800-PetMeds.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the board changes positively, as they reflect a commitment to strategic board composition and refreshment.
• Employees may be impacted by the company's transformation strategy and the new leadership team.
• Customers may benefit from the company's focus on expanding its business across the broader pet wellness ecosystem.

Next Steps

• Peter Batushansky will serve on the Board until the 2025 annual meeting of shareholders.
• Dr. Gian Fulgoni will retire from the Board at the 2025 annual shareholders meeting.
• The Board size will be reduced from seven to six persons effective immediately upon Mr. Fulgonis departure from the Board simultaneously with the Companys 2025 annual shareholders meeting.

Key Dates

Keywords

Board of Directors, Peter Batushansky, Gian Fulgoni, PetMed Express, Appointment, Retirement, Corporate Governance